Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 4/20 | 0.36 |
| ▸ | DHODH | Q02127 | 5/20 | 0.35 |
| ▸ | NPC1 | O15118 | 4/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742271 | 1.00 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL29742278 | 1.00 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28559681 | 0.92 | DHODH (0.40) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28562623 | 0.91 | GAA (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL24455254 | 0.90 | DHODH (0.37) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28574410 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28576661 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL28563781 | 0.90 | DHODH (0.38) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL25665425 | 0.90 | KEAP1 (0.39) | GAAKEAP1NFE2L2PKMMAPK1 | |
| SCHEMBL20560768 | 0.89 | PKM (0.37) | GAAPKMMAPK1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4247813-B1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3- YL)PYRIDOF[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC (US) | 2025-12-24 | — | — | EP | claimed |
| US-12441729-B2 | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | AMGEN INC. (US) | 2025-10-14 | — | — | US | claimed |
| US-20250129072-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC. (US) | 2025-04-24 | — | — | US | claimed |
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | AMGEN INC. (US) | 2024-01-25 | — | — | US | claimed |
| CN-116507624-A | Process for preparing 7-chloro-6-fluoro-1- (2-isopropyl-4-methylpyridin-3-yl) pyrido F [2,3-D ] pyrimidine-2, 4 (1H, 3H) -dione | 美国安进公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114907259-A | Synthetic method of Sotolira intermediate | 常州中氪生命科学技术有限公司 | 2022-08-16 | — | — | CN | claimed |
| EP-3974429-A1 | PRECURSORS OF KRAS G12C INHIBITORS | Amgen Inc. (US) | 2022-03-30 | — | — | EP | claimed |
| EP-4700026-A3 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3- YL)PYRIDOF[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | Amgen Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4234546-B1 | IMPROVED SYNTHESIS OF KEY INTERMEDIATE OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | AMGEN INC. (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4685160-A2 | COMBINATION THERAPY INCLUDING A KRASG12C INHIBITOR AND ONE OR MORE ADDITIONAL PHARMACEUTICALLY ACTIVE AGENTS FOR THE TREATMENT OF CANCERS | Amgen Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | AMGEN INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2019-12-31 | — | — | US | disclosed |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| WO-2019051291-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051291-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| WO-2018217651-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | GAA 1458/4885KEAP1 726/4885NFE2L2 2351/4885 |
| US-20240025896-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | HINT1, DPYD, NME2 | GAA 1829/4885KEAP1 3753/4885NFE2L2 2327/4885 |
| US-12441729-B2 | Process for preparing 7-chloro-6-fluoro-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione | HINT1, NME2, DPYD | GAA 1800/4885KEAP1 3196/4885NFE2L2 2008/4885 |
| US-20250129072-A1 | PROCESS FOR PREPARING 7-CHLORO-6-FLUORO-1-(2-ISOPROPYL-4-METHYLPYRIDIN-3-YL)PYRIDO[2,3-D]PYRIMIDINE-2,4(1H,3H)-DIONE | HINT1, NME2, DPYD | GAA 1800/4885KEAP1 3196/4885NFE2L2 2008/4885 |
| US-10519146-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | GAA 2321/4885KEAP1 344/4885NFE2L2 3211/4885 |
| US-20190077801-A1 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2041/4885KEAP1 271/4885NFE2L2 2542/4885 |
| US-20180334454-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | GAA 2321/4885KEAP1 344/4885NFE2L2 3211/4885 |
| US-20250388579-A1 | SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND | KRAS, NRAS, BRAF | GAA 4799/4885KEAP1 1498/4885NFE2L2 1868/4885 |
| US-12582657-B2 | Combination therapy including a KRAS G12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers | KRAS, NRAS, BRAF | GAA 4829/4885KEAP1 1062/4885NFE2L2 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.